Compare First Solar, Inc. (FSLR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Organon & Co. Common Stock — how do they compare? First Solar, Inc. trades at $175.25 (market cap $19.25B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: First Solar, Inc. is far larger — about 5.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 76 Days and Organon & Co. Common Stock for 0 Days on average.
| FSLR | OGN | |
|---|---|---|
Market Cap | $19.25B | $3.61B |
Volume | 2,086,427 | 1,808,049 |
Sector | Energy | Health |
52-Week High | $318.30 | $13.81 |
52-Week Low | $172.11 | $5.70 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $17.71B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $186.60, up 3.83% today, but remains in a bearish technical trend with resistance near $190. The company reported strong revenue growth to $5.22 billion in 2025 and a net income margin of 32.47%, though it missed Q4 2025 EPS estimates. Recent news includes a patent lawsuit against competitors and elevated put option activity, reflecting mixed sentiment amid sector-wide pressures from high borrowing costs.
FSLR presents a value opportunity with a low P/E of 11.5 and analyst consensus price target of $269, but faces risks from solar industry headwinds and technical bearish signals. Earnings beats in recent quarters support fundamentals, yet political and financing challenges could limit near-term upside.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
